Wuhan Hongsheng Reproductive Health Traditional Chinese Medicine Hospital Co., Ltd.

Wuhan Hong'ang Reproductive Health Traditional Chinese Medicine Hospital (formerly Wuhan Hongsheng Infertility Traditional Chinese Medicine Hospital) is a wholly-owned subsidiary of Humanwell Healthcare (Group) Co., Ltd. It is the first traditional Chinese medicine medical institution in Hubei Province approved by the Hubei Provincial Department of Health in 1984 to diagnose and treat infertility as well as gynecological and andrological diseases with "specialized department, expert, specialized method, and specialized medicine". With ancestral secret recipes and authentic medicinal materials as its medical characteristics, it inherits and promotes the essence of reproductive medicine, and has developed and promoted nearly twenty pure traditional Chinese medicine preparations, which have respectively obtained national medicine approval numbers and approval numbers from the Provincial Food and Drug Administration. All are independent intellectual property rights owned by the hospital.
Humanwell Healthcare (Group) Co., Ltd. (hereinafter referred to as "Humanwell Healthcare") was established on March 30, 1993, and was listed on the Shanghai Stock Exchange on June 6, 1997 (code: 600079.SH). Humanwell Healthcare is the first listed private high-tech enterprise in Hubei Province and the first listed company in Wuhan East Lake New Technology Development Zone. After nearly 20 years of development, Humanwell Healthcare has become a comprehensive pharmaceutical industry group, with more than 10 pharmaceutical manufacturing enterprises and multiple pharmaceutical commercial enterprises under its jurisdiction. It is the pharmaceutical enterprise in Hubei Province with the strongest production capacity, the most complete dosage forms, the most varieties, and the most abundant resources. It has become a leading enterprise in the pharmaceutical industry of Hubei Province, a top 50 enterprise in China's pharmaceutical industry, and a *** enterprise technology center. It is one of the most recognized and most investment-worthy pharmaceutical listed companies in the capital market.
Humanwell Healthcare adheres to the strategy of being the "* in segmented markets" in the pharmaceutical field. It has established a leading position in domestic fields such as anesthetics, fertility-regulating drugs, and Uyghur medicine, and is cultivating its own unique competitiveness in multiple segmented fields such as biological products and genetic engineering drugs; at the same time, it is building a leading regional pharmaceutical commercial enterprise to achieve positive interaction between industry and commerce. Humanwell Healthcare is actively integrating into the international market, establishing a * globally operating pharmaceutical company, and striving to become a mainstream supplier of generic drugs in mainstream international markets such as Europe and America.
Humanwell Healthcare will use the "strength" in "segmented markets" to achieve the "greatness" in the "pharmaceutical market". Its goal is to achieve annual sales revenue of over ten billion during the "Twelfth Five-Year Plan" period, enter the top 20 in China's pharmaceutical industry, and become one of the * in China's pharmaceutical industry!
Talent philosophy: talents have gradients, training has levels, development has goals, careers have paths, providing unlimited space for talent creation!
Hospital website: www.***
Humanwell website: *